Entity

Time filter

Source Type

Graz, Austria

Khunnonkwao P.,Suranaree University of Technology | Boontawan P.,Suranaree University of Technology | Haltrich D.,University of Vienna | Maischberger T.,ProtAffin Biotechnologie | Boontawan A.,Suranaree University of Technology
Process Biochemistry | Year: 2012

The vapor permeation-assisted esterification of l-(+)-lactic acid and ethanol was investigated using a zeolite membrane. Pervaporation and vapor permeation were initially investigated for dehydration performances, and the latter showed much better results. The molecular sieve property of the membrane resulted in a high separation factor of over 1000 for all conditions. The maximum flux was 10.24 kg/(m2 h) at a feed temperature of 145 °C, a water feed concentration of 10 wt%, and a feed pressure of 4.0 bars, respectively. For vapor permeation-assisted esterification using synthetic solutions, the productivity and ethyl lactate yield strongly depended on the dehydration rate. Realistic purifications were performed with fermentation broths of Pediococcus pentosaceus as the lactic acid producer. Experimental results revealed that most of the lactic acid was converted into ethyl lactate at the final stage of the reaction. After distillation and hydrolysis, high purity l-(+)-lactic acid was obtained with more than 95% recovery yields. © 2012 Elsevier Ltd.


Patent
ProtAffin Biotechnologie | Date: 2012-12-17

Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.


A novel approach for inhibiting FGF2/FGFR1-mediated signalling is presented which is based on FGFR1 mutations to introduce higher affinity for the natural GAG co-receptors into the soluble part of the FGF1 receptor, preferably into the D2/D3 domains. Such recombinant drugs are expected to disrupt the natural FGF2/FGFR1/GAG triple complex by competing with the wtFGFR1 for GAG binding


Patent
ProtAffin Biotechnologie | Date: 2010-09-13

The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.


Patent
ProtAffin Biotechnologie | Date: 2010-01-29

Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.

Discover hidden collaborations